ClinicalTrials.gg
CompletedNCT02958436Updated Nov 8, 2017

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

A Phase 1 interventional study of REGN3500 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN3500 in healthy adult males and females

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Safety
  • Tolerability
  • Pharmacokinetics
  • REGN3500
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \</= 33 kg/m2
  • In good health based on medical history, physical examination, vital signs, and laboratory testing
  • Normal (ECG) and blood pressure
  • Able to comply with clinic visits and study-related procedures
  • Able to sign an

Exclusion criteria

Exclusion Criteria:

  • Significant abnormalities in hematology, clinical chemistry, urinalysis, medical history
  • Current smoker or recent history (within 3 months)
  • History of tuberculosis, , or hepatic disease
  • Known sensitivity to doxycycline or other ingredients of study drug
  • History of multiple/severe allergies
  • Pregnant or breastfeeding women, or not currently using adequate
  • Participation in another drug study within 4 weeks
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Dose regimen 1 of REGN3500 (IV) versus placebo

    Drug: REGN3500 · Drug: Placebo

  • Experimental
    Cohort 2

    Dose regimen 2 of REGN3500 (IV) versus placebo

    Drug: REGN3500 · Drug: Placebo

  • Experimental
    Cohort 3

    Dose regimen 3 of REGN3500 (IV) versus placebo

    Drug: REGN3500 · Drug: Placebo

  • Experimental
    Cohort 4

    Dose regimen 4 of REGN3500 (SC) versus placebo

    Drug: REGN3500 · Drug: Placebo

  • Experimental
    Cohort 5

    Dose regimen 5 of REGN3500 (IV) versus placebo

    Drug: REGN3500 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and severity of treatment-emergent adverse events in subjects treated with REGN3500

    Time frame: Up to 293 days after dosing

Secondary outcomes

  1. Obtain the pharmacokinetic parameters (Cmax) that describe the serum concentration time profile of REGN3500

    Time frame: Obtain serum samples pre-dose, immediately post-dose (infusion or injection end), 1, 2, 4, 8 (for subcutaneous) and 12 (for intravenous) hours after dosing

  2. Obtain the pharmacokinetic parameters (Tmax) that describe the serum concentration time profile of REGN3500

    Time frame: Obtain serum samples pre-dose, immediately post-dose (infusion or injection end), 1, 2, 4, 8 (for subcutaneous) and 12 (for intravenous) hours after dosing

  3. Obtain the pharmacokinetic parameters (AUClast) that describe the serum concentration time profile of REGN3500

    Time frame: Obtain serum samples pre-dose, immediately post-dose (infusion or injection end), 1, 2, 4, 8 (for subcutaneous) and 12 (for intravenous) hours after dosing

07

Study locations

1 site
  • Site 1
    Ghent, Belgium
08

References and documents

Publications

  • Kosloski MP, Kalliolias GD, Xu CR, Harel S, Lai CH, Zheng W, Davis JD, Kamal MA. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395. doi: 10.1111/cts.13157. Epub 2021 Sep 29. PubMed 34523807 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jun 2017, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Nov 8, 2016
StartActual
Aug 2016
Primary completionActual
Jun 18, 2017
CompletionActual
Oct 3, 2017
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02958436
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Aug 2016
Primary completion
Jun 18, 2017
Completion
Oct 3, 2017
Last update
Nov 8, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion